Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
OSA itself predicted the incidence of MACCE in non-obese patients.
Read Full NewsA retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.
For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.
Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
1.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
2.
Alkem introduces cetuximab under the trade name Cetuxa in India.
3.
Formaldehyde releasers found in common personal care products used especially by Black and Latina women
4.
FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC
5.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
1.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
2.
Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care
3.
Understanding Iron Saturation Levels in Your Blood
4.
Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma
5.
Vaccines that can help prevent cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
5.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge